Oncotarget

Corrections:

Correction: Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma

PDF  |  How to cite

Oncotarget. 2018; 9:36250-36250. https://doi.org/10.18632/oncotarget.26387

Metrics: PDF 1017 views  |   ?  

Suliman Boulos1,*, Min Chul Park2,*, Marian Zeibak3, Shen Yun Foo4, Yoon Kyung Jeon5, Young Tae Kim6, Alex Motzik3, Sagi Tshori7, Tamar Hamburger8, Sunghoon Kim2, Hovav Nechushtan1 and Ehud Razin3,4

1 Department of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
2 Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea
3 Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel
4 NUS-HUJ-CREATE Cellular & Molecular Mechanisms of Inflammation Program, Department of Microbiology and Immunology, National University of Singapore, Singapore
5 Department of Pathology, Seoul National University Hospital, Seoul, Korea
6 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea
7 Kaplan Medical Center, Rehovot, Israel
8 Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
* These authors have contributed equally to this work

Published: November 16, 2018

This article has been corrected: The correct title for figure 5 is given below:

Figure 5: Subgroup analysis of nuclear P207 LysRS according to Lymph nodes positivity. Disease free survival of wild-type EGFR patients with (positive) or without (negative) cytosolic (A) and nuclear (B) LysRS. Disease free survival of mutated EGFR patients with (positive) or without (negative) cytosolic (C) and nuclear (D) LysRS.

Original article: Oncotarget. 2017; 8:65186-65198. DOI: https://doi.org/10.18632/oncotarget.18053.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26387